Activation of the Ca2+-sensing receptor increases renal claudin-14 expression and urinary Ca2+ excretion Am J Physiol Renal Physiol, Mar 2013; 304: F761 - F769.
[Cldn14]
An SRF/miR-1 axis regulates NCX1 and Annexin A5 protein levels in the normal and failing heart Cardiovasc Res, Mar 2013; 10.1093/cvr/cvt042.
[JunD]
Betaglycan Alters NFB-TGFß2 Cross Talk to Reduce Survival of Human Granulosa Tumor Cells Mol. Endocrinol., Mar 2013; 27: 466 - 479.
[SMAD3]
Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression Carcinogenesis, Mar 2013; 34: 550 - 559.
[cathepsin B]
KCNA3 Other names: HGK5; HLK3; HPCN3; HUKIII; KV1.3; MK3; PCN3
Host Cell
CHL
cDNA Clone:
SC118765
Format:
2 x 1 mL frozen cell vials each containing 1 x 10E6 cells
Mycoplasma:
Negative by DNA staining and direct culture methods (ATTC - detailed information available upon request)
Cell Line Validation:
Gene expression: qPCR experiments determined specific over-expression of KNA3A.Figure 1.
Functional validationThe basic biophysical properties, expression levels, and pharmacology of Kv1.3-CHL cells were assessed using the IonWorks planar array electrophysiology platform.
Current-voltage relationship. Figure 2
Expression statistics. Figure 3
Pharmacology (Figure 4) - Inhibition of hKv1.3 K+ currents by known K+ channel blockers.
Background:
Kv1.3 is a voltage-gated K+ channel that contributes to the delayed rectifier K+ current in a range of cell types. Kv1.3 is potently blocked by the peptides ShK, charybdotoxin and margatoxin and small molecules such as PAP-1.Selective blockers of Kv1.3 inhibit calcium signaling, cytokine production and proliferation of T lymphocytes in vitro and ameliorate disease in animal models of multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus and contact dermatitis.
Figure 1: In a SYBR green qPCR experiment, specific over-expression of KCN3A was determined using gene specific primers. Data are shown as fold over-expression after normalization against GAPDH
Figure 2: Current-voltage relationship for hKv1.3 channels stably expressed in CHL cells (A); filled circles - CHL-Kv1.3, filled triangles - CHL-wild type cells. Representative recordings from CHL-Kv1.3 (B) and CHL-wild type cells (C). Experiments were conducted from a holding potential of -80mV. The depolarising step length was 200ms.
Figure 3: Expression profile: outward K+ currents of >0.6 nA were observed in 337 of 341 cells (99%), with a mean amplitude of 2.60 ± 0.132 nA (n=341; mean ± S.D.). The peak current in each cell, evoked from a depolarising pulse to +40 mV, was divided into 0.2 nA bins to create the population histogram
Figure 4: Summary pharmacology of hKv1.3-CHL cell line. Voltage-clamp recordings were made using repeated gating steps, Vh -80mV, Vstep +40mV, 1 Hz, pulse duration 250ms. Control traces in black, test compounds in red. IC50 values were obtained by fitting concentration-response curves to values for inhibition of the 1st (peak and sustained) and 5th pulse in the train (µM, shown in table). Use-dependent and open channel block can be assessed within this protocol.
